The study is testing the efficacy of cancer treatments that are selected based on genomic markers driving patients' tumors, regardless of cancer type.
Strata will refer individuals with HER-2 mutations identified through its screening trial for consideration as subjects in Puma's SUMMIT trial.
The company intends to use the funds to support submission of its NGS assay to the FDA, adoption of its testing by more health systems, and continued R&D.
The company now partners with 10 healthcare systems to provide free NGS testing to all advanced cancer patients and plans to present patient data this summer.
Get the latest news in the Genetics and Genomics industries right here. For the week of Dec 15, 2017.
The company hopes to build enrollment of men with advanced prostate cancer within its larger Strata Trial — which provides free targeted sequencing and tracks its impact on clinical trial enrollment.
Strata will help Epizyme identify cancer patients for enrollment in a Phase II trial of its non-Hodgkins lymphoma drug tazemetostat.
Strata will refer castration-resistant prostate cancer patients with BRCA and ATM mutations for potential enrollment in Clovis' Rubraca studies.
The study will provide no-cost tumor sequencing and clinical trial matching to an estimated 100,000 patients with advanced cancers.
The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.
People reports that researchers have uncovered genetic variants that lead people to always feel full.
Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.
In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.